Last week, Sarepta Therapeutics made some major announcements that have sent shockwaves through the biotech industry. The company revealed plans to lay off hundreds of employees, disclosed a third recent patient death in a separate disease, and engaged in a heated battle with the FDA over the agency’s decision to remove its Duchenne gene therapy from the market.
In a recent interview with our reporters, Jared Whitlock and Lei Lei Wu, we delved into the chaotic events of the past few days and discussed the implications moving forward. We are committed to uncovering the truth behind these developments by gathering insights from the company, patients, investors, and regulators.
For those interested in learning more about this unfolding story, you can tune in to our latest episode on our YouTube channel or listen to us on Spotify and Apple Podcasts by searching for “Endpoints News.”
If you are a current or former employee of Sarepta, a patient, or a healthcare provider with valuable information to share, we encourage you to reach out to us. Our episode features a segment on how to contact us securely through the encrypted messaging app, Signal. Feel free to connect with Jared at jaredwhitlock.73 and Lei Lei at leileiwu.24 – rest assured, we prioritize your privacy and confidentiality.
Thank you for your continued support and interest in our coverage of these critical developments. Stay informed and stay tuned for more updates on this evolving story. – Drew
